Research Analysts Issue Forecasts for ARWR FY2030 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Analysts at B. Riley issued their FY2030 earnings estimates for shares of Arrowhead Pharmaceuticals in a report issued on Tuesday, November 25th. B. Riley analyst M. El-Saadi expects that the biotechnology company will post earnings per share of $6.48 for the year. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share.

ARWR has been the topic of several other research reports. Royal Bank Of Canada boosted their target price on shares of Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the company an “outperform” rating in a research note on Wednesday, November 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. Morgan Stanley upped their target price on shares of Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, Piper Sandler boosted their price objective on Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $48.56.

Arrowhead Pharmaceuticals Stock Up 23.3%

ARWR opened at $57.71 on Thursday. Arrowhead Pharmaceuticals has a fifty-two week low of $9.57 and a fifty-two week high of $59.15. The company has a market capitalization of $7.98 billion, a P/E ratio of -45.09 and a beta of 1.27. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. The firm’s fifty day moving average price is $38.18 and its two-hundred day moving average price is $25.40.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Moody Lynn & Lieberson LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $213,000. CWM LLC increased its position in shares of Arrowhead Pharmaceuticals by 159.4% during the second quarter. CWM LLC now owns 11,415 shares of the biotechnology company’s stock worth $180,000 after purchasing an additional 7,014 shares in the last quarter. Hsbc Holdings PLC purchased a new position in shares of Arrowhead Pharmaceuticals in the first quarter worth about $173,000. Pinnacle Associates Ltd. boosted its holdings in shares of Arrowhead Pharmaceuticals by 49.9% during the 2nd quarter. Pinnacle Associates Ltd. now owns 211,561 shares of the biotechnology company’s stock worth $3,343,000 after purchasing an additional 70,399 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in Arrowhead Pharmaceuticals by 75.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,308 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total value of $700,000.00. Following the completion of the transaction, the insider directly owned 212,122 shares in the company, valued at approximately $7,424,270. The trade was a 8.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders sold 50,000 shares of company stock worth $1,525,000. Corporate insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.